AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications

15Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

Abstract

With the development of68Ga and177Lu radiochemistry, theranostic approaches in mod-ern nuclear medicine enabling patient-centered personalized medicine applications have been growing in the last decade. In conjunction with the search for new relevant molecular targets, the design of innovative chelating agents to easily form stable complexes with various radiometals for theranostic applications has gained evident momentum. Initially conceived for magnetic resonance imaging applications, the chelating agent AAZTA features a mesocyclic seven-membered diaze-pane ring, conferring some of the properties of both acyclic and macrocyclic chelating agents. De-scribed in the early 2000s, AAZTA and its derivatives exhibited interesting properties once com-plexed with metals and radiometals, combining a fast kinetic of formation with a slow kinetic of dissociation. Importantly, the extremely short coordination reaction times allowed by AAZTA derivatives were particularly suitable for short half-life radioelements (i.e.,68Ga). In view of these par-ticular characteristics, the scope of this review is to provide a survey on the design, synthesis, and applications in the nuclear medicine/radiopharmacy field of AAZTA-derived chelators.

Cite

CITATION STYLE

APA

Fersing, C., Masurier, N., Rubira, L., Deshayes, E., & Lisowski, V. (2022, February 1). AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications. Pharmaceuticals. MDPI. https://doi.org/10.3390/ph15020234

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free